TY - JOUR
T1 - Targeting Src family kinases in anti-cancer therapies
T2 - Turning promise into triumph
AU - Zhang, Siyuan
AU - Yu, Dihua
N1 - Funding Information:
The authors thank Yu laboratory members for valuable comments on this manuscript. Dr S. Zhang holds a Susan G. Komen Breast Cancer Foundation Postdoctoral Fellowship (KG091316) and NIH/NCI K99/R00 Award (CA158066). Dr D. Yu holds the Hubert L. & Olive Stringer Distinguished Chair in Basic Science at the M. D. Anderson Cancer Center. This work is partially supported by grants from NIH PO1-CA099031 project 4, the Susan G. Komen Breast Cancer Foundation KG091020, and the Cancer Prevention and Research Institute of Texas RP100726 (D. Yu). We thank Mr Samuel Brady for reading the manuscript.
PY - 2012/3
Y1 - 2012/3
N2 - Src is a non-receptor tyrosine kinase that is deregulated in many types of cancer. Decades of research have revealed the crucial role of Src in many aspects of tumor development, including proliferation, survival, adhesion, migration, invasion and, most importantly, metastasis, in multiple tumor types. Despite extensive preclinical evidence that warrants targeting Src as a promising therapeutic approach for cancer, Src inhibitor(s) showed only minimal therapeutic activity in various types of solid tumors when used as a single agent in recent early-phase clinical trials. In this review, we highlight the most recent advances from preclinical studies and clinical trials that shed light on potential clinical use of Src inhibitor-containing combinatorial regimens in overcoming resistance to current anticancer therapies and in preventing metastatic recurrence.
AB - Src is a non-receptor tyrosine kinase that is deregulated in many types of cancer. Decades of research have revealed the crucial role of Src in many aspects of tumor development, including proliferation, survival, adhesion, migration, invasion and, most importantly, metastasis, in multiple tumor types. Despite extensive preclinical evidence that warrants targeting Src as a promising therapeutic approach for cancer, Src inhibitor(s) showed only minimal therapeutic activity in various types of solid tumors when used as a single agent in recent early-phase clinical trials. In this review, we highlight the most recent advances from preclinical studies and clinical trials that shed light on potential clinical use of Src inhibitor-containing combinatorial regimens in overcoming resistance to current anticancer therapies and in preventing metastatic recurrence.
UR - http://www.scopus.com/inward/record.url?scp=84857916018&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857916018&partnerID=8YFLogxK
U2 - 10.1016/j.tips.2011.11.002
DO - 10.1016/j.tips.2011.11.002
M3 - Review article
C2 - 22153719
AN - SCOPUS:84857916018
SN - 0165-6147
VL - 33
SP - 122
EP - 128
JO - Trends in Pharmacological Sciences
JF - Trends in Pharmacological Sciences
IS - 3
ER -